Natural History of Obesity Due to POMC, PCSK1, and LEPR Deficiency and the Impact of Setmelanotide
Естественное течение ожирения вследствие дефицита POMC, PCSK1 и LEPR и влияние сетмеланотида
2022-04-15
SCID: 54.1/ab5v7vjy
Discuss with AI
LEPR deficiencyMC4R pathwayPCSK1 deficiencyPOMC deficiencySetmelanotide
Figures from the paper
Abstract (AI)
Context: can disrupt signaling through the melanocortin-4 receptor (MC4R) pathway, resulting in hyperphagia and severe early-onset obesity. In pivotal Phase 3 clinical trials, treatment with the MC4R agonist setmelanotide reduced hunger and weight in patients with obesity due to proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency. Objective: To characterize the historical weight trajectory in these patients. Methods: This analysis included data from 2 pivotal single-arm, open-label, Phase 3 trials (NCT02896192, NCT03287960). These were multicenter trials. Patients had obesity due to POMC/PCSK1 or LEPR deficiency. During the trial, patients were treated with setmelanotide. Historical data on measured weight and height were obtained during screening. Results: A total of 17 patients (POMC, n = 8; PCSK1, n = 1; LEPR, n = 8) with historical weight and height data were included in this analysis. Before setmelanotide treatment, patients with obesity due to POMC/PCSK1 or LEPR deficiency were above the 95th percentile for weight throughout childhood, demonstrated continuous weight gain, and did not show long-term weight loss upon interventions (eg, diet, surgery, exercise). Setmelanotide treatment attenuated weight and body mass index trajectories over the observation period of 1 year. Conclusion: In patients with POMC, PCSK1, or LEPR deficiency, traditional interventions for weight loss had limited impact on the trajectory of severe early-onset obesity. However, setmelanotide treatment attenuated weight and body mass index trajectories and led to weight loss associated with health benefits in most individuals.
Key Findings
1
Diet, exercise, and bariatric surgery produced limited long-term weight loss in individuals with these genetic deficiencies.
2
In a cohort of 17 patients, one year of setmelanotide treatment attenuated weight and BMI trajectories.
3
Patients with POMC, PCSK1, or LEPR deficiency remained above the 95th weight percentile throughout childhood and experienced continuous weight gain.
4
Setmelanotide induced weight loss associated with health benefits in most treated individuals.
5
The findings support MC4R-pathway activation as a targeted treatment approach for severe early-onset obesity caused by POMC, PCSK1, or LEPR deficiency.
Research Object
Patients with severe early-onset obesity due to POMC, PCSK1, or LEPR deficiency
Research Subject
Historical weight and body mass index trajectories and their modification by setmelanotide treatment, including responses to traditional weight-loss interventions
Publication Details
Publication Date
2022-04-15
Journal
Publisher
ISSN
Cited by
70
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest